Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
Jun Tian, Jonathan H. Chen, Sherry Chao, et al.
Nature Medicine (2023) Vol. 29, Iss. 2, pp. 458-466
Open Access | Times Cited: 108

Showing 1-25 of 108 citing articles:

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors
Mohamed A. Gouda, Vivek Subbiah
American Society of Clinical Oncology Educational Book (2023), Iss. 43
Open Access | Times Cited: 52
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Aphrothiti J. Hanrahan, Ziyu Chen, Neal Rosen, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 3, pp. 224-247
Closed Access | Times Cited: 42
Advancements in combining targeted therapy and immunotherapy for colorectal cancer
Manisha Singh, Van K. Morris, Irfan Bandey, et al.
Trends in cancer (2024) Vol. 10, Iss. 7, pp. 598-609
Closed Access | Times Cited: 24
The evolving landscape of tissue‐agnostic therapies in precision oncology
Vivek Subbiah, Mohamed A. Gouda, Bettina Ryll, et al.
CA A Cancer Journal for Clinicians (2024) Vol. 74, Iss. 5, pp. 433-452
Open Access | Times Cited: 21
Recent developments in immunotherapy for gastrointestinal tract cancers
Xiaoyi Chong, Yelizhati Madeti, Jieyuan Cai, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 20
Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Minae An, Arnav Mehta, Byung‐Hoon Min, et al.
Cancer Discovery (2024) Vol. 14, Iss. 5, pp. 766-785
Open Access | Times Cited: 18
Targeting the EGFR signalling pathway in metastatic colorectal cancer
Stefania Napolitano, Giulia Martini, Davide Ciardiello, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 7, pp. 664-676
Closed Access | Times Cited: 16
Overcoming cancer therapy resistance: From drug innovation to therapeutics
Jinrui Wei, Meng‐Yi Lu, Tian‐Hua Wei, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101229-101229
Closed Access | Times Cited: 2
Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer
Nadia Saoudi, Javier Ros, Iosune Baraibar, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 412-412
Open Access | Times Cited: 13
From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies
Ehsan Gharib, Gilles A. Robichaud
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9463-9463
Open Access | Times Cited: 9
The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers
Meagan B. Ryan, Bradley Quade, Natasha Schenk, et al.
Cancer Discovery (2024) Vol. 14, Iss. 7, pp. 1190-1205
Open Access | Times Cited: 8
Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy
Liuqing Yang, Ye Yang, Jing Zhang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Base editing screens define the genetic landscape of cancer drug resistance mechanisms
Matthew A. Coelho, Magdalena E. Strauß, Alex Watterson, et al.
Nature Genetics (2024) Vol. 56, Iss. 11, pp. 2479-2492
Open Access | Times Cited: 8
An immunohistochemical and molecular genetic study of 60 colorectal carcinoma brain metastases in pursuit of predictive biomarkers for cancer therapy
Jerzy Lasota, Maciej Kaczorowski, Małgorzata Chłopek, et al.
Human Pathology (2025) Vol. 155, pp. 105717-105717
Closed Access | Times Cited: 1
BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives
Stefania Napolitano, Davide Ciardiello, Eleonora Cioli, et al.
Cancer Treatment Reviews (2025) Vol. 134, pp. 102905-102905
Open Access | Times Cited: 1
Machine learning identifies clinical tumor mutation landscape pathways of resistance to checkpoint inhibitor therapy in NSCLC
Vitalay Fomin, WeiQing Venus So, R Barbieri, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 3, pp. e009092-e009092
Open Access | Times Cited: 1
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers
Javier Ros, Marta Rodríguez-Castells, Nadia Saoudi, et al.
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 8, pp. 797-806
Closed Access | Times Cited: 18
Spatial analysis of human lung cancer reveals organized immune hubs enriched for stem-like CD8 T cells and associated with immunotherapy response
Jonathan H. Chen, Linda T. Nieman, Maxwell Spurrell, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 17
High-Fidelity Identification of Single Nucleotide Polymorphism by Type V CRISPR Systems
Yawen He, Shengjie Shao, Juhong Chen
ACS Sensors (2023) Vol. 8, Iss. 12, pp. 4478-4483
Closed Access | Times Cited: 16
First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial
Anne Hansen Ree, Jūratė Šaltytė Benth, Hanne Hamre, et al.
British Journal of Cancer (2024) Vol. 130, Iss. 12, pp. 1921-1928
Open Access | Times Cited: 7
Clinical Use of Molecular Biomarkers in Canine and Feline Oncology: Current and Future
Heike Aupperle‐Lellbach, Alexandra Kehl, Simone de Brot, et al.
Veterinary Sciences (2024) Vol. 11, Iss. 5, pp. 199-199
Open Access | Times Cited: 6
MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-Fos and JunB
Xiu‐Jian Wang, Tao Xiao, Pengjie Chen, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 6
BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer
Margherita Ambrosini, David Tougeron, Dominik Paul Modest, et al.
European Journal of Cancer (2024) Vol. 210, pp. 114290-114290
Closed Access | Times Cited: 5
Colorectal Cancer with BRAF V600E Mutation: Trends in Immune Checkpoint Inhibitor Treatment
Mengling Liu, Qing Liu, Keshu Hu, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 204, pp. 104497-104497
Closed Access | Times Cited: 5
BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of Resistance: A Review of the Literature
Patrícia Guerrero, Víctor Albarrán, María San Román, et al.
Cancers (2023) Vol. 15, Iss. 21, pp. 5243-5243
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top